{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T17:25:00Z","timestamp":1763400300587,"version":"3.44.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40261-025-01465-4","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T11:19:17Z","timestamp":1754047157000},"page":"627-642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Memantine for the Treatment of Primary Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"45","author":[{"given":"Houlin","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Donlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragana","family":"Bugarski-Kirola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mujeeb U.","family":"Shad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajoy P.","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludmil","family":"Mitrev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Echeverria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Dibato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selene R. T.","family":"Veerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Aiyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas N.","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Villarreal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shafiqur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maju M.","family":"Koola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"1465_CR1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. American Psychiatric Publishing; 2013.","edition":"5"},{"issue":"1","key":"1465_CR2","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2021.11","volume":"64","author":"S Galderisi","year":"2021","unstructured":"Galderisi S, Mucci A, Dollfus S, et al. EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry. 2021;64(1): e23.","journal-title":"Eur Psychiatry"},{"issue":"2","key":"1465_CR3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/schbul\/sbj053","volume":"32","author":"B Kirkpatrick","year":"2006","unstructured":"Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR Jr. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214\u20139.","journal-title":"Schizophr Bull"},{"key":"1465_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/NDT.S225643","volume":"16","author":"CU Correll","year":"2020","unstructured":"Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519\u201334.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2\u20133","key":"1465_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.schres.2014.10.043","volume":"161","author":"J Ventura","year":"2015","unstructured":"Ventura J, Subotnik KL, Gitlin MJ, et al. Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later. Schizophr Res. 2015;161(2\u20133):407\u201313.","journal-title":"Schizophr Res"},{"issue":"1","key":"1465_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.schres.2015.03.033","volume":"165","author":"MT Strassnig","year":"2015","unstructured":"Strassnig MT, Raykov T, O\u2019Gorman C, et al. Determinants of different aspects of everyday outcome in schizophrenia: the roles of negative symptoms, cognition, and functional capacity. Schizophr Res. 2015;165(1):76\u201382.","journal-title":"Schizophr Res"},{"issue":"6","key":"1465_CR7","first-page":"495","volume":"44","author":"HW Tsang","year":"2010","unstructured":"Tsang HW, Leung AY, Chung RC, Bell M, Cheung WM. Review on vocational predictors: a systematic review of predictors of vocational outcomes among individuals with schizophrenia: an update since 1998. Aust N Z J Psychiatry. 2010;44(6):495\u2013504.","journal-title":"Aust N Z J Psychiatry"},{"issue":"5","key":"1465_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1600-0447.2011.01814.x","volume":"125","author":"D Vancampfort","year":"2012","unstructured":"Vancampfort D, Knapen J, Probst M, et al. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand. 2012;125(5):352\u201362.","journal-title":"Acta Psychiatr Scand"},{"issue":"3\u20134","key":"1465_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2152\/jmi.58.167","volume":"58","author":"M Tomotake","year":"2011","unstructured":"Tomotake M. Quality of life and its predictors in people with schizophrenia. J Med Invest. 2011;58(3\u20134):167\u201374.","journal-title":"J Med Invest"},{"issue":"1","key":"1465_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0920-9964(97)00043-1","volume":"26","author":"HL Provencher","year":"1997","unstructured":"Provencher HL, Mueser KT. Positive and negative symptom behaviors and caregiver burden in the relatives of persons with schizophrenia. Schizophr Res. 1997;26(1):71\u201380.","journal-title":"Schizophr Res"},{"key":"1465_CR11","doi-asserted-by":"crossref","unstructured":"Kadakia A, Catillon M, Fan Q, et al. The economic burden of schizophrenia in the United States. J Clin Psychiatry. 2022;83(6:43278.","DOI":"10.4088\/JCP.22m14458"},{"key":"1465_CR12","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2147\/NDT.S419397","volume":"19","author":"M Racher","year":"2023","unstructured":"Racher M, Carpenter W, Kane JM. A patient-clinician discussion of current challenges in schizophrenia part 2: negative symptoms in schizophrenia. Neuropsychiatr Dis Treat. 2023;19:1339\u201345.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"10","key":"1465_CR13","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1176\/appi.ps.52.10.1358","volume":"52","author":"JS Brekke","year":"2001","unstructured":"Brekke JS, Prindle C, Bae SW, Long JD. Risks for individuals with schizophrenia who are living in the community. Psychiatr Serv. 2001;52(10):1358\u201366.","journal-title":"Psychiatr Serv"},{"issue":"102(1)","key":"1465_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0165-1781(01)00245-1","volume":"10","author":"G Bryson","year":"2001","unstructured":"Bryson G, Whelahan HA, Bell M. Memory and executive function impairments in deficit syndrome schizophrenia. Psychiatry Res. 2001;10(102(1)):29\u201337.","journal-title":"Psychiatry Res"},{"key":"1465_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.schres.2016.06.024","volume":"186","author":"S Dollfus","year":"2017","unstructured":"Dollfus S, Lyne J. Negative symptoms: history of the concept and their position in diagnosis of schizophrenia. Schizophr Res. 2017;186:3\u20137.","journal-title":"Schizophr Res"},{"issue":"5","key":"1465_CR16","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.euroneuro.2013.09.011","volume":"24","author":"JC Neill","year":"2014","unstructured":"Neill JC, Harte MK, Haddad PM, Lydall ES, Dwyer DM. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans. Eur Neuropsychopharmacol. 2014;24(5):822\u201335.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1465_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.schres.2016.02.035","volume":"186","author":"TM Lincoln","year":"2017","unstructured":"Lincoln TM, Dollfus S, Lyne J. Current developments and challenges in the assessment of negative symptoms. Schizophr Res. 2017;186:8\u201318.","journal-title":"Schizophr Res"},{"issue":"4","key":"1465_CR18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0006-3223(91)90287-V","volume":"30","author":"R Tandon","year":"1991","unstructured":"Tandon R, Greden JF. Negative symptoms of schizophrenia: the need for conceptual clarity. Biol Psychiatry. 1991;30(4):321\u20135.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"1465_CR19","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1176\/ajp.145.5.578","volume":"145","author":"WT Carpenter Jr","year":"1988","unstructured":"Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145(5):578\u201383.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1465_CR20","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/schbul\/11.3.471","volume":"11","author":"TJ Crow","year":"1985","unstructured":"Crow TJ. The two-syndrome concept: origins and current status. Schizophr Bull. 1985;11(3):471\u201386.","journal-title":"Schizophr Bull"},{"key":"1465_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.schres.2023.07.010","volume":"258","author":"SR Marder","year":"2023","unstructured":"Marder SR, Umbricht D. Negative symptoms in schizophrenia: newly emerging measurements, pathways, and treatments. Schizophr Res. 2023;258:71\u20137. https:\/\/doi.org\/10.1016\/j.schres.2023.07.010.","journal-title":"Schizophr Res"},{"issue":"1","key":"1465_CR22","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2021.13","volume":"64","author":"S Galderisi","year":"2021","unstructured":"Galderisi S, Kaiser S, Bitter I, et al. EPA guidance on treatment of negative symptoms in schizophrenia. Eur Psychiatry. 2021;64(1): e21. https:\/\/doi.org\/10.1192\/j.eurpsy.2021.13.","journal-title":"Eur Psychiatry"},{"issue":"7","key":"1465_CR23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","volume":"74","author":"CU Correll","year":"2017","unstructured":"Correll CU, Rubio JM, Inczedy-Farkas G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatr. 2017;74(7):675\u201384. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.0624.","journal-title":"JAMA Psychiatr"},{"issue":"5","key":"1465_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","volume":"76","author":"J Tiihonen","year":"2019","unstructured":"Tiihonen J, Taipale H, Mehtala J, et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatr. 2019;76(5):499\u2013507. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.4320.","journal-title":"JAMA Psychiatr"},{"issue":"3","key":"1465_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S2215-0366(24)00370-5","volume":"12","author":"DJ Nutt","year":"2025","unstructured":"Nutt DJ. Drug development in psychiatry: 50 years of failure and how to resuscitate it. Lancet Psychiatry. 2025;12(3):228\u201338. https:\/\/doi.org\/10.1016\/S2215-0366(24)00370-5.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1465_CR26","first-page":"12","volume":"9","author":"DC Javitt","year":"1987","unstructured":"Javitt DC. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry. 1987;9(1):12\u201335.","journal-title":"Hillside J Clin Psychiatry"},{"issue":"10","key":"1465_CR27","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301\u20138.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"1465_CR28","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s002590000372","volume":"27","author":"RA Bressan","year":"2000","unstructured":"Bressan RA, Pilowsky LS. Imaging the glutamatergic system in vivo\u2013relevance to schizophrenia. Eur J Nucl Med. 2000;27(11):1723\u201331.","journal-title":"Eur J Nucl Med"},{"issue":"2\u20133","key":"1465_CR29","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0165-0173(99)00050-8","volume":"31","author":"A Carlsson","year":"2000","unstructured":"Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia - therapeutic implications. Brain Res Brain Res Rev. 2000;31(2\u20133):342\u20139.","journal-title":"Brain Res Brain Res Rev"},{"issue":"1","key":"1465_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00213-004-2109-y","volume":"179","author":"A Egerton","year":"2005","unstructured":"Egerton A, Reid L, McKerchar CE, Morris BJ, Pratt JA. Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology. 2005;179(1):77\u201384.","journal-title":"Psychopharmacology"},{"issue":"5","key":"1465_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1177\/1073858405279692","volume":"11","author":"CR Yang","year":"2005","unstructured":"Yang CR, Chen L. Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment. Neuroscientist. 2005;11(5):452\u201370.","journal-title":"Neuroscientist"},{"key":"1465_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-016-0003-3","volume":"3","author":"K Nakazawa","year":"2017","unstructured":"Nakazawa K, Jeevakumar V, Nakao K. Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia. NPJ Schizophr. 2017;3: 7.","journal-title":"NPJ Schizophr"},{"issue":"1","key":"1465_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01549-7","volume":"11","author":"A Espana","year":"2021","unstructured":"Espana A, Seth H, Jezequel J, et al. Alteration of NMDA receptor trafficking as a cellular hallmark of psychosis. Transl Psychiatry. 2021;11(1): 444.","journal-title":"Transl Psychiatry"},{"key":"1465_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.641047","volume":"15","author":"Q Wu","year":"2021","unstructured":"Wu Q, Huang J, Wu R. Drugs based on NMDAR hypofunction hypothesis in schizophrenia. Front Neurosci. 2021;15: 641047.","journal-title":"Front Neurosci"},{"key":"1465_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/NDT.S125800","volume":"13","author":"K Tsutsui","year":"2017","unstructured":"Tsutsui K, Kanbayashi T, Takaki M, et al. N-Methyl-D-aspartate receptor antibody could be a cause of catatonic symptoms in psychiatric patients: case reports and methods for detection. Neuropsychiatr Dis Treat. 2017;13:339\u201345.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"1465_CR36","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.biopsych.2017.05.007","volume":"82","author":"A Ramirez","year":"2017","unstructured":"Ramirez A, Arbuckle MR. The N-methyl-D-aspartate receptor: memory, madness, and more. Biol Psychiatry. 2017;82(1):e1\u20133.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"1465_CR37","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","volume":"101","author":"JH Krystal","year":"2019","unstructured":"Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS. Ketamine: a paradigm shift for depression research and treatment. Neuron. 2019;101(5):774\u20138.","journal-title":"Neuron"},{"issue":"2\u20133","key":"1465_CR38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/s0165-0173(99)00002-8","volume":"29","author":"GE Duncan","year":"1999","unstructured":"Duncan GE, Sheitman BB, Lieberman JA. An integrated view of pathophysiological models of schizophrenia. Brain Res Brain Res Rev. 1999;29(2\u20133):250\u201364. https:\/\/doi.org\/10.1016\/s0165-0173(99)00002-8.","journal-title":"Brain Res Brain Res Rev"},{"key":"1465_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0074-7742(06)78003-5","volume":"78","author":"DC Javitt","year":"2007","unstructured":"Javitt DC. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol. 2007;78:69\u2013108. https:\/\/doi.org\/10.1016\/S0074-7742(06)78003-5.","journal-title":"Int Rev Neurobiol"},{"issue":"3","key":"1465_CR40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.31887\/DCNS.2010.12.3\/jcoyle","volume":"12","author":"JT Coyle","year":"2010","unstructured":"Coyle JT, Balu D, Benneyworth M, Basu A, Roseman A. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues Clin Neurosci. 2010;12(3):359\u201382.","journal-title":"Dialogues Clin Neurosci"},{"issue":"5","key":"1465_CR41","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.tins.2008.02.005","volume":"31","author":"JE Lisman","year":"2008","unstructured":"Lisman JE, Coyle JT, Green RW, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008;31(5):234\u201342. https:\/\/doi.org\/10.1016\/j.tins.2008.02.005.","journal-title":"Trends Neurosci"},{"issue":"1","key":"1465_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/npp.2011.181","volume":"37","author":"B Moghaddam","year":"2012","unstructured":"Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37(1):4\u201315. https:\/\/doi.org\/10.1038\/npp.2011.181.","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl 1","key":"1465_CR43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4088\/JCP.13049su1c.04","volume":"75","author":"L Citrome","year":"2014","unstructured":"Citrome L. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J Clin Psychiatry. 2014;75(Suppl 1):21\u20136. https:\/\/doi.org\/10.4088\/JCP.13049su1c.04.","journal-title":"J Clin Psychiatry"},{"issue":"2\u20133","key":"1465_CR44","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.schres.2013.07.026","volume":"150","author":"C Arango","year":"2013","unstructured":"Arango C, Garibaldi G, Marder SR. Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res. 2013;150(2\u20133):346\u201352. https:\/\/doi.org\/10.1016\/j.schres.2013.07.026.","journal-title":"Schizophr Res"},{"issue":"6\u20137","key":"1465_CR45","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.neuint.2005.12.021","volume":"48","author":"L Hertz","year":"2006","unstructured":"Hertz L. Glutamate, a neurotransmitter\u2013and so much more. A synopsis of Wierzba III. Neurochem Int. 2006;48(6\u20137):416\u201325. https:\/\/doi.org\/10.1016\/j.neuint.2005.12.021.","journal-title":"Neurochem Int"},{"issue":"1","key":"1465_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00002826-200101000-00008","volume":"24","author":"SI Deutsch","year":"2001","unstructured":"Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol. 2001;24(1):43\u20139. https:\/\/doi.org\/10.1097\/00002826-200101000-00008.","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"1465_CR47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","volume":"6","author":"JW Johnson","year":"2006","unstructured":"Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol. 2006;6(1):61\u20137.","journal-title":"Curr Opin Pharmacol"},{"key":"1465_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2013.00035","volume":"4","author":"G Orellana","year":"2013","unstructured":"Orellana G, Slachevsky A. Executive functioning in schizophrenia. Front Psychiatry. 2013;4: 35.","journal-title":"Front Psychiatry"},{"issue":"10","key":"1465_CR49","doi-asserted-by":"publisher","first-page":"607","DOI":"10.33588\/rn.4210.2005252","volume":"42","author":"A Tanovic","year":"2006","unstructured":"Tanovic A, Alfaro V. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer\u2019s disease and vascular dementia]. Rev Neurol. 2006;42(10):607\u201316.","journal-title":"Rev Neurol"},{"issue":"4","key":"1465_CR50","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/npp.2014.276","volume":"40","author":"JC Bartsch","year":"2015","unstructured":"Bartsch JC, Fidzinski P, Huck JH, et al. Enhanced dopamine-dependent hippocampal plasticity after single MK-801 application. Neuropsychopharmacology. 2015;40(4):987\u201395.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1465_CR51","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","volume":"24","author":"CG Parsons","year":"2013","unstructured":"Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer\u2019s disease. Neurotox Res. 2013;24(3):358\u201369.","journal-title":"Neurotox Res"},{"issue":"3","key":"1465_CR52","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10522-020-09860-4","volume":"21","author":"ME Conway","year":"2020","unstructured":"Conway ME. Alzheimer\u2019s disease: targeting the glutamatergic system. Biogerontology. 2020;21(3):257\u201374.","journal-title":"Biogerontology"},{"key":"1465_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109737","author":"PK Tari","year":"2023","unstructured":"Tari PK, Parsons CG, Collingridge GL, Rammes G. Memantine: updating a rare success story in pro-cognitive therapeutics. Neuropharmacology. 2023. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109737.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1465_CR54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0028-3908(98)00161-0","volume":"38","author":"CG Parsons","year":"1999","unstructured":"Parsons CG, Danysz W, Bartmann A, et al. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology. 1999;38(1):85\u2013108.","journal-title":"Neuropharmacology"},{"issue":"6","key":"1465_CR55","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.neuropharm.2007.07.013","volume":"53","author":"CG Parsons","year":"2007","unstructured":"Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system\u2013too little activation is bad, too much is even worse. Neuropharmacology. 2007;53(6):699\u2013723.","journal-title":"Neuropharmacology"},{"issue":"12","key":"1465_CR56","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/0028-3908(93)90029-3","volume":"32","author":"CG Parsons","year":"1993","unstructured":"Parsons CG, Gruner R, Rozental J, Millar J, Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology. 1993;32(12):1337\u201350.","journal-title":"Neuropharmacology"},{"issue":"2\u20133","key":"1465_CR57","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF03033787","volume":"2","author":"W Danysz","year":"2000","unstructured":"Danysz W, Parsons CG, Mobius HJ, Stoffler A, Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer\u2019s disease\u2013a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res. 2000;2(2\u20133):85\u201397.","journal-title":"Neurotox Res"},{"issue":"4","key":"1465_CR58","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/aps.2009.24","volume":"30","author":"XX Dong","year":"2009","unstructured":"Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30(4):379\u201387.","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"1465_CR59","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0028-3908(99)00060-X","volume":"38","author":"T Frankiewicz","year":"1999","unstructured":"Frankiewicz T, Parsons CG. Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. Neuropharmacology. 1999;38(9):1253\u20139.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1465_CR60","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1152\/jn.1997.77.1.309","volume":"77","author":"TA Blanpied","year":"1997","unstructured":"Blanpied TA, Boeckman FA, Aizenman E, Johnson JW. Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol. 1997;77(1):309\u201323.","journal-title":"J Neurophysiol"},{"issue":"3","key":"1465_CR61","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199\u2013214.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"1465_CR62","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1527-3458.2003.tb00254.x","volume":"9","author":"MA Rogawski","year":"2003","unstructured":"Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer\u2019s disease. CNS Drug Rev. 2003;9(3):275\u2013308.","journal-title":"CNS Drug Rev"},{"issue":"40","key":"1465_CR63","doi-asserted-by":"publisher","first-page":"9686","DOI":"10.1523\/JNEUROSCI.1173-17.2017","volume":"37","author":"NG Glasgow","year":"2017","unstructured":"Glasgow NG, Povysheva NV, Azofeifa AM, Johnson JW. Memantine and ketamine differentially alter NMDA receptor desensitization. J Neurosci. 2017;37(40):9686\u2013704.","journal-title":"J Neurosci"},{"issue":"3\u20134","key":"1465_CR64","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0014-2999(83)90315-1","volume":"96","author":"SC Berry","year":"1983","unstructured":"Berry SC, Burton NR, Anis NA, Lodge D. Stereoselective effects of two phencyclidine derivatives on N-methylaspartate excitation of spinal neurones in the cat and rat. Eur J Pharmacol. 1983;96(3\u20134):261\u20137.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1465_CR65","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/070674376701200217","volume":"12","author":"T Itil","year":"1967","unstructured":"Itil T, Keskiner A, Kiremitci N, Holden JM. Effect of phencyclidine in chronic schizophrenics. Can Psychiatr Assoc J. 1967;12(2):209\u201312.","journal-title":"Can Psychiatr Assoc J"},{"key":"1465_CR66","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/archpsyc.1959.03590060113013","volume":"1","author":"G Rosenbaum","year":"1959","unstructured":"Rosenbaum G, Cohen BD, Luby ED, Gottlieb JS, Yelen D. Comparison of sernyl with other drugs: simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception. AMA Arch Gen Psychiatry. 1959;1:651\u20136.","journal-title":"AMA Arch Gen Psychiatry"},{"key":"1465_CR67","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/archpsyc.1962.01710230063007","volume":"6","author":"BD Cohen","year":"1962","unstructured":"Cohen BD, Rosenbaum G, Luby ED, Gottlieb JS. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium; part II. Symbolic and sequential thinking. Arch Gen Psychiatry. 1962;6:395\u2013401.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"1465_CR68","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/archneurpsyc.1959.02340150095011","volume":"81","author":"ED Luby","year":"1959","unstructured":"Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry. 1959;81(3):363\u20139.","journal-title":"AMA Arch Neurol Psychiatry"},{"issue":"2","key":"1465_CR69","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1476-5381.1983.tb11031.x","volume":"79","author":"NA Anis","year":"1983","unstructured":"Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol. 1983;79(2):565\u201375.","journal-title":"Br J Pharmacol"},{"key":"1465_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2019.00185","volume":"12","author":"G Lee","year":"2019","unstructured":"Lee G, Zhou Y. NMDAR hypofunction animal models of schizophrenia. Front Mol Neurosci. 2019;12: 185.","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"1465_CR71","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1254\/fpj.124.145","volume":"124","author":"T Kato","year":"2004","unstructured":"Kato T. Memantine: a therapeutic drug for Alzheimer\u2019s disease and the comparison with MK-801. Nihon Yakurigaku Zasshi. 2004;124(3):145\u201351.","journal-title":"Nihon Yakurigaku Zasshi."},{"issue":"2","key":"1465_CR72","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/ejn.13128","volume":"43","author":"I Riebe","year":"2016","unstructured":"Riebe I, Seth H, Culley G, et al. Tonically active NMDA receptors\u2013a signalling mechanism critical for interneuronal excitability in the CA1 stratum radiatum. Eur J Neurosci. 2016;43(2):169\u201378.","journal-title":"Eur J Neurosci"},{"key":"1465_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2020.101986","volume":"200","author":"KA Alkadhi","year":"2021","unstructured":"Alkadhi KA. NMDA receptor-independent LTP in mammalian nervous system. Prog Neurobiol. 2021;200: 101986.","journal-title":"Prog Neurobiol"},{"issue":"6","key":"1465_CR74","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1111\/j.1471-4159.2006.03991.x","volume":"97","author":"HS Chen","year":"2006","unstructured":"Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem. 2006;97(6):1611\u201326.","journal-title":"J Neurochem"},{"issue":"Suppl 1","key":"1465_CR75","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.33549\/physiolres.932678","volume":"63","author":"V Vyklicky","year":"2014","unstructured":"Vyklicky V, Korinek M, Smejkalova T, et al. Structure, function, and pharmacology of NMDA receptor channels. Physiol Res. 2014;63(Suppl 1):S191-203.","journal-title":"Physiol Res"},{"issue":"11","key":"1465_CR76","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2165\/00003495-200666110-00015","volume":"66","author":"DM Robinson","year":"2006","unstructured":"Robinson DM, Keating GM. Memantine: a review of its use in Alzheimer\u2019s disease. Drugs. 2006;66(11):1515\u201334.","journal-title":"Drugs"},{"issue":"8","key":"1465_CR77","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1176\/appi.ajp.2008.07071135","volume":"165","author":"R Freedman","year":"2008","unstructured":"Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008;165(8):1040\u20137. https:\/\/doi.org\/10.1176\/appi.ajp.2008.07071135.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"1465_CR78","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.27163","volume":"7","author":"NR Wong","year":"2024","unstructured":"Wong NR, Rubin LH, Harrington CK, et al. Hippocampal availability of the alpha7 nicotinic acetylcholine receptor in recent-onset psychosis. JAMA Netw Open. 2024;7(8): e2427163. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.27163.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1465_CR79","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2174\/138920111794480589","volume":"12","author":"AJ Kucinski","year":"2011","unstructured":"Kucinski AJ, Stachowiak MK, Wersinger SR, Lippiello PM, Bencherif M. Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia. Curr Pharm Biotechnol. 2011;12(3):437\u201348. https:\/\/doi.org\/10.2174\/138920111794480589.","journal-title":"Curr Pharm Biotechnol"},{"key":"1465_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113285","volume":"291","author":"MM Koola","year":"2020","unstructured":"Koola MM, Looney SW, Hong H, Pillai A, Hou W. Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement. Psychiatry Res. 2020;291: 113285.","journal-title":"Psychiatry Res"},{"issue":"243","key":"1465_CR81","first-page":"160","volume":"41","author":"M Flis","year":"2016","unstructured":"Flis M, Szymona K, Morylowska-Topolska J, et al. The kynurenic acid hypothesis - a new look at etiopathogenesis and treatment of schizophrenia. Pol Merkur Lekarski. 2016;41(243):160\u20134.","journal-title":"Pol Merkur Lekarski"},{"key":"1465_CR82","unstructured":"Kuns B RA, Varghese D. Memantine. StatPearls Publishing. Updated July 11, 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500025\/. Accessed 06 Jan 2024."},{"key":"1465_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/biom10081134","author":"T Kikuchi","year":"2020","unstructured":"Kikuchi T. Is memantine effective as an NMDA-receptor antagonist in adjunctive therapy for schizophrenia? Biomolecules. 2020. https:\/\/doi.org\/10.3390\/biom10081134.","journal-title":"Biomolecules"},{"issue":"4","key":"1465_CR84","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/schbul\/sbu170","volume":"41","author":"P Fusar-Poli","year":"2015","unstructured":"Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41(4):892\u20139.","journal-title":"Schizophr Bull"},{"issue":"3","key":"1465_CR85","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/0269881120965937","volume":"35","author":"KK Goh","year":"2021","unstructured":"Goh KK, Wu TH, Chen CH, Lu ML. Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: a meta-analysis of randomised, placebo-controlled trials. J Psychopharmacol. 2021;35(3):236\u201352.","journal-title":"J Psychopharmacol"},{"issue":"10","key":"1465_CR86","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.4088\/JCP.08m04935gry","volume":"70","author":"D de Lucena","year":"2009","unstructured":"de Lucena D, Fernandes BS, Berk M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry. 2009;70(10):1416\u201323.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"1465_CR87","first-page":"696","volume":"54","author":"A Fakhri","year":"2016","unstructured":"Fakhri A, Pakseresht S, Haghdoost MR, et al. Memantine enhances the effect of olanzapine in patients with schizophrenia: a randomized, placebo-controlled study. Acta Med Iran. 2016;54(11):696\u2013703.","journal-title":"Acta Med Iran"},{"issue":"4","key":"1465_CR88","first-page":"261","volume":"22","author":"J Gu","year":"2012","unstructured":"Gu J, Wu Y, Tang L. A controlled study of clozapine plus memantine in schizophrenia negative sypmtoms. In Chines J Clin Psychiatry. 2012;22(4):261\u20133.","journal-title":"In Chines. J Clin Psychiatry."},{"issue":"6","key":"1465_CR89","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1097\/JCP.0000000000001115","volume":"39","author":"F Hassanpour","year":"2019","unstructured":"Hassanpour F, Zarghami M, Mouodi S, et al. Adjunctive memantine treatment of schizophrenia: a double-blind, randomized placebo-controlled study. J Clin Psychopharmacol. 2019;39(6):634\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"1465_CR90","doi-asserted-by":"publisher","first-page":"166","DOI":"10.4306\/pi.2012.9.2.166","volume":"9","author":"JG Lee","year":"2012","unstructured":"Lee JG, Lee SW, Lee BJ, et al. Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Investig. 2012;9(2):166\u201373.","journal-title":"Psychiatry Investig"},{"issue":"5","key":"1465_CR91","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/npp.2008.200","volume":"34","author":"JA Lieberman","year":"2009","unstructured":"Lieberman JA, Papadakis K, Csernansky J, et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology. 2009;34(5):1322\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"1465_CR92","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.psychres.2016.09.028","volume":"247","author":"R Mazinani","year":"2017","unstructured":"Mazinani R, Nejati S, Khodaei M. Effects of memantine added to risperidone on the symptoms of schizophrenia: a randomized double-blind, placebo-controlled clinical trial. Psychiatry Res. 2017;247:291\u20135.","journal-title":"Psychiatry Res"},{"issue":"3","key":"1465_CR93","first-page":"108","volume":"45","author":"V Omranifard","year":"2017","unstructured":"Omranifard V, Rajabi F, Mohammadian-Sichani M, Maracy MR. The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a double-blind, randomized, controlled trial. Actas Esp Psiquiatr. 2017;45(3):108\u201315.","journal-title":"Actas Esp Psiquiatr"},{"issue":"3","key":"1465_CR94","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/JCP.0b013e31828b50a7","volume":"33","author":"F Rezaei","year":"2013","unstructured":"Rezaei F, Mohammad-Karimi M, Seddighi S, et al. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2013;33(3):336\u201342.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1465_CR95","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1055\/a-0970-9310","volume":"53","author":"M Schaefer","year":"2020","unstructured":"Schaefer M, Sarkar S, Theophil I, et al. Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. Pharmacopsychiatry. 2020;53(1):21\u20139.","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl","key":"1465_CR96","first-page":"122","volume":"17","author":"M Tavakoli-Ardakani","year":"2018","unstructured":"Tavakoli-Ardakani M, Abbaspour H, Farhadi Nasab A, Mazaheri Meibodi A, Kheradmand A. Study of the effect of Memantine on negative sign in patients with schizophrenia and schizoaffective disorders. Iran J Pharm Res. 2018;17(Suppl):122\u20139.","journal-title":"Iran J Pharm Res"},{"issue":"9","key":"1465_CR97","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1017\/S0033291716000398","volume":"46","author":"SR Veerman","year":"2016","unstructured":"Veerman SR, Schulte PF, Smith JD, de Haan L. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Psychol Med. 2016;46(9):1909\u201321.","journal-title":"Psychol Med"},{"issue":"14","key":"1465_CR98","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s00213-017-4616-7","volume":"234","author":"T Kishi","year":"2017","unstructured":"Kishi T, Matsuda Y, Iwata N. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. Psychopharmacology. 2017;234(14):2113\u201325.","journal-title":"Psychopharmacology"},{"key":"1465_CR99","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.schres.2019.05.019","volume":"209","author":"W Zheng","year":"2019","unstructured":"Zheng W, Zhu XM, Zhang QE, et al. Adjunctive memantine for major mental disorders: a systematic review and meta-analysis of randomized double-blind controlled trials. Schizophr Res. 2019;209:12\u201321.","journal-title":"Schizophr Res"},{"issue":"4","key":"1465_CR100","first-page":"253","volume":"30","author":"S Vayisoglu","year":"2019","unstructured":"Vayisoglu S, Karahan S, Anil Yagcioglu AE. Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. Turk Psikiyatri Derg. 2019;30(4):253\u20139.","journal-title":"Turk Psikiyatri Derg"},{"issue":"4","key":"1465_CR101","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00213-013-3064-2","volume":"228","author":"M Noroozian","year":"2013","unstructured":"Noroozian M, Ghasemi S, Hosseini SM, et al. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology. 2013;228(4):595\u2013602.","journal-title":"Psychopharmacology"},{"key":"1465_CR102","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.schres.2024.08.001","volume":"274","author":"WP Horan","year":"2024","unstructured":"Horan WP, Targum SD, Claxton A, et al. Efficacy of KarXT on negative symptoms in acute schizophrenia: a post hoc analysis of pooled data from 3 trials. Schizophr Res. 2024;274:57\u201365. https:\/\/doi.org\/10.1016\/j.schres.2024.08.001.","journal-title":"Schizophr Res"},{"issue":"5","key":"1465_CR103","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336\u201341.","journal-title":"Int J Surg"},{"issue":"3","key":"1465_CR104","doi-asserted-by":"publisher","first-page":"258","DOI":"10.18502\/ijps.v18i3.13002","volume":"18","author":"SA Hosseini","year":"2023","unstructured":"Hosseini SA, Sepehrmanesh Z, Gilasi H, Ghoraishi FS. The Effect of Memantine Versus Folic Acid on Cognitive Impairment in Patients with Schizophrenia: A Randomized Clinical Trial. Iran J Psychiatry. 2023;18(3):258\u201365. https:\/\/doi.org\/10.18502\/ijps.v18i3.13002.","journal-title":"Iran J Psychiatry"},{"issue":"4","key":"1465_CR105","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/schbul\/sbx054","volume":"43","author":"WT Carpenter Jr.","year":"2017","unstructured":"Carpenter WT Jr., Buchanan RW. Negative symptom therapeutics. Schizophr Bull. 2017;43(4):681\u20132.","journal-title":"Schizophr Bull"},{"issue":"l4898","key":"1465_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.l4898","volume":"366","author":"J Sterne","year":"2019","unstructured":"Sterne J, Savovi\u0107 J, Page M, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366(l4898):1\u20138. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"11","key":"1465_CR107","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/sim.1752","volume":"23","author":"JP Higgins","year":"2004","unstructured":"Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med. 2004;23(11):1663\u201382. https:\/\/doi.org\/10.1002\/sim.1752.","journal-title":"Stat Med"},{"issue":"14","key":"1465_CR108","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer\u2019s disease. N Engl J Med. 2003;348(14):1333\u201341. https:\/\/doi.org\/10.1056\/NEJMoa013128.","journal-title":"N Engl J Med"},{"key":"1465_CR109","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2147\/ndt.s5021","volume":"5","author":"U Puangthong","year":"2009","unstructured":"Puangthong U, Hsiung GY. Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer\u2019s disease. Neuropsychiatr Dis Treat. 2009;5:553\u201361. https:\/\/doi.org\/10.2147\/ndt.s5021.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1465_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/npjschz.2016.3","volume":"2","author":"IE Sommer","year":"2016","unstructured":"Sommer IE, Bearden CE, van Dellen E, et al. Early interventions in risk groups for schizophrenia: what are we waiting for? NPJ Schizophr. 2016;2: 16003. https:\/\/doi.org\/10.1038\/npjschz.2016.3.","journal-title":"NPJ Schizophr"},{"issue":"3","key":"1465_CR111","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1017\/S0033291721000246","volume":"51","author":"K Griffiths","year":"2021","unstructured":"Griffiths K, Millgate E, Egerton A, MacCabe JH. Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis. Psychol Med. 2021;51(3):376\u201386. https:\/\/doi.org\/10.1017\/S0033291721000246.","journal-title":"Psychol Med"},{"issue":"14","key":"1465_CR112","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1017\/S0033291719001995","volume":"49","author":"N Cakici","year":"2019","unstructured":"Cakici N, van Beveren NJM, Judge-Hundal G, Koola MM, Sommer IEC. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med. 2019;49(14):2307\u201319. https:\/\/doi.org\/10.1017\/S0033291719001995.","journal-title":"Psychol Med"},{"key":"1465_CR113","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","volume":"191","author":"GE Hunt","year":"2018","unstructured":"Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990\u20132017: systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234\u201358.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"1465_CR114","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.jpsychires.2012.04.019","volume":"46","author":"MM Koola","year":"2012","unstructured":"Koola MM, McMahon RP, Wehring HJ, et al. Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders. J Psychiatr Res. 2012;46(8):987\u201393.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"1465_CR115","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/15504263.2012.647345","volume":"8","author":"MM Koola","year":"2012","unstructured":"Koola MM, Wehring HJ, Kelly DL. The potential role of long-acting injectable antipsychotics in people with schizophrenia and comorbid substance use. J Dual Diagn. 2012;8(1):50\u201361.","journal-title":"J Dual Diagn"},{"issue":"3","key":"1465_CR116","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/schbul\/sbp016","volume":"35","author":"ND Volkow","year":"2009","unstructured":"Volkow ND. Substance use disorders in schizophrenia\u2013clinical implications of comorbidity. Schizophr Bull. 2009;35(3):469\u201372.","journal-title":"Schizophr Bull"},{"key":"1465_CR117","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.schres.2017.04.016","volume":"194","author":"JY Khokhar","year":"2018","unstructured":"Khokhar JY, Dwiel LL, Henricks AM, Doucette WT, Green AI. The link between schizophrenia and substance use disorder: a unifying hypothesis. Schizophr Res. 2018;194:78\u201385.","journal-title":"Schizophr Res"},{"issue":"1","key":"1465_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/wps.20807","volume":"20","author":"WT Carpenter","year":"2021","unstructured":"Carpenter WT. Primary psychosis: more to know, much more to do. World Psychiatry. 2021;20(1):1\u20132.","journal-title":"World Psychiatry"},{"issue":"1","key":"1465_CR119","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jemermed.2018.04.014","volume":"55","author":"Y Etlouba","year":"2018","unstructured":"Etlouba Y, Laher A, Motara F, Moolla M, Ariefdien N. First presentation with psychotic symptoms to the emergency department. J Emerg Med. 2018;55(1):78\u201386.","journal-title":"J Emerg Med"},{"issue":"1","key":"1465_CR120","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/wps.20001","volume":"12","author":"MS Keshavan","year":"2013","unstructured":"Keshavan MS, Kaneko Y. Secondary psychoses: an update. World Psychiatry. 2013;12(1):4\u201315.","journal-title":"World Psychiatry"},{"issue":"7","key":"1465_CR121","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nrd.2016.88","volume":"15","author":"A Bespalov","year":"2016","unstructured":"Bespalov A, Steckler T, Altevogt B, et al. Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets. Nat Rev Drug Discov. 2016;15(7):516.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1465_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hup.2758","volume":"36","author":"MM Koola","year":"2021","unstructured":"Koola MM. Alpha7 nicotinic-N-methyl-D-aspartate hypothesis in the treatment of schizophrenia and beyond. Hum Psychopharmacol. 2021;36(1):1\u201316. https:\/\/doi.org\/10.1002\/hup.2758.","journal-title":"Hum Psychopharmacol"},{"issue":"1","key":"1465_CR123","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","volume":"82","author":"D Bugarski-Kirola","year":"2017","unstructured":"Bugarski-Kirola D, Blaettler T, Arango C, et al. Bitopertin in negative symptoms of schizophrenia-results from the phase III flashlyte and daylyte studies. Biol Psychiatry. 2017;82(1):8\u201316.","journal-title":"Biol Psychiatry"},{"issue":"4","key":"1465_CR124","first-page":"233","volume":"34","author":"MC Grabb","year":"2020","unstructured":"Grabb MC, Hillefors M, Potter WZ. The NIMH \u201cfast-fail trials\u201d (FAST) initiative: rationale, promise, and progress. Pharmaceut Med. 2020;34(4):233\u201345.","journal-title":"Pharmaceut Med"},{"issue":"7061","key":"1465_CR125","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/437942a","volume":"437","author":"S Frantz","year":"2005","unstructured":"Frantz S. Drug discovery: playing dirty. Nature. 2005;437(7061):942\u20133.","journal-title":"Nature"},{"issue":"3","key":"1465_CR126","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000494495","volume":"4","author":"MM Koola","year":"2018","unstructured":"Koola MM. Potential role of antipsychotic-galantamine-memantine combination in the treatment of positive, cognitive, and negative symptoms of schizophrenia. Complex Psychiatry. 2018;4(3):134\u201348.","journal-title":"Complex Psychiatry"},{"issue":"4","key":"1465_CR127","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd1346","volume":"3","author":"BL Roth","year":"2004","unstructured":"Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004;3(4):353\u20139.","journal-title":"Nat Rev Drug Discov"},{"key":"1465_CR128","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.trci.2019.09.019","volume":"5","author":"J Fessel","year":"2019","unstructured":"Fessel J. Prevention of Alzheimer\u2019s disease by treating mild cognitive impairment with combinations chosen from eight available drugs. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2019;5:780\u20138.","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"key":"1465_CR129","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.schres.2018.11.022","volume":"206","author":"MM Koola","year":"2019","unstructured":"Koola MM. Can N-acetylcysteine, varenicline, or the combination prevent psychosis by enhancing mismatch negativity? Schizophr Res. 2019;206:452\u20133.","journal-title":"Schizophr Res"},{"issue":"2","key":"1465_CR130","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/15504263.2023.2293854","volume":"20","author":"J Donlon","year":"2024","unstructured":"Donlon J, Kumari P, Varghese S, Bai M. Integrative pharmacology in the treatment of substance use disorders. J Dual Diagn. 2024;20(2):132\u201377.","journal-title":"J Dual Diagn"},{"issue":"9","key":"1465_CR131","doi-asserted-by":"publisher","first-page":"e1307","DOI":"10.4088\/JCP.17f11998","volume":"78","author":"C Andrade","year":"2017","unstructured":"Andrade C. Memantine as an augmentation treatment for schizophrenia: limitations of meta-analysis for evidence-based evaluation of research. J Clin Psychiatry. 2017;78(9):e1307\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1465_CR132","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/schbul\/sbq059","volume":"37","author":"B Kirkpatrick","year":"2011","unstructured":"Kirkpatrick B, Strauss GP, Nguyen L, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011;37(2):300\u20135.","journal-title":"Schizophr Bull"},{"issue":"1","key":"1465_CR133","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1192\/bjp.2023.69","volume":"223","author":"E Fernandez-Egea","year":"2023","unstructured":"Fernandez-Egea E, Mucci A, Lee J, Kirkpatrick B. A new era for the negative symptoms of schizophrenia. Br J Psychiatry. 2023;223(1):269\u201370. https:\/\/doi.org\/10.1192\/bjp.2023.69.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"1465_CR134","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1192\/bjp.2023.68","volume":"223","author":"B Kirkpatrick","year":"2023","unstructured":"Kirkpatrick B, Luther L, Strauss GP. Negative symptoms in the clinic: we treat what we can describe. Br J Psychiatry. 2023;223(1):271\u20132. https:\/\/doi.org\/10.1192\/bjp.2023.68.","journal-title":"Br J Psychiatry"},{"key":"1465_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.766692","volume":"12","author":"SN Mosolov","year":"2021","unstructured":"Mosolov SN, Yaltonskaya PA. Primary and secondary negative symptoms in schizophrenia. Front Psychiatry. 2021;12: 766692. https:\/\/doi.org\/10.3389\/fpsyt.2021.766692.","journal-title":"Front Psychiatry."},{"issue":"1\u20132","key":"1465_CR136","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000515066","volume":"7","author":"MY Bai","year":"2021","unstructured":"Bai MY, Lovejoy DB, Guillemin GJ, et al. Galantamine-memantine combination and kynurenine pathway enzyme inhibitors in the treatment of neuropsychiatric disorders. Complex Psychiatry. 2021;7(1\u20132):19\u201333. https:\/\/doi.org\/10.1159\/000515066.","journal-title":"Complex Psychiatry"},{"issue":"7","key":"1465_CR137","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.eurpsy.2014.01.007","volume":"29","author":"G Fervaha","year":"2014","unstructured":"Fervaha G, Foussias G, Agid O, Remington G. Impact of primary negative symptoms on functional outcomes in schizophrenia. Eur Psychiatry. 2014;29(7):449\u201355.","journal-title":"Eur Psychiatry"},{"issue":"3","key":"1465_CR138","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/schbul\/11.3.440","volume":"11","author":"WT Carpenter Jr.","year":"1985","unstructured":"Carpenter WT Jr., Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull. 1985;11(3):440\u201352.","journal-title":"Schizophr Bull"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01465-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01465-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01465-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T06:59:18Z","timestamp":1757487558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01465-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":138,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1465"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01465-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"13 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Institutional review board approval was not required for this meta-analysis. PRISMA guidelines were used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"The authors received no financial support for the research, authorship, and\/or publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The meta-analysis was performed using RevMan 5.4.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Studies included in this meta-analysis were openly available and sourced from PubMed, Cochrane Library, PsycINFO, EMBASE, or China Journal Net databases. Three authors provided original datasets. The data for this study are available upon request. The original datasets of certain studies are only available by contacting the corresponding authors of those studies.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Houlin Hong: Writing\u2014Methodology, Software, Validation, Formal analysis, Investigation, Original draft preparation, Visualization. Jack Donlon: Writing\u2014Investigation, Original draft preparation, Visualization. Martin Schaefer: Writing\u2014Review and Editing. Susanne Sarkar: Writing\u2014Review and Editing. Dragana Bugarski-Kirola: Writing\u2014Review and Editing. Mujeeb U. Shad: Writing\u2014Review and Editing. Wei Hou: Methodology, Validation, Formal analysis, Writing\u2014Review and Editing. Matthias Kirschner: Writing\u2014Review and Editing. Sajoy P. Varghese: Writing\u2014Review and Editing. Ludmil Mitrev: Writing\u2014Review and Editing. Valentina Echeverria: Writing\u2014Review and Editing. John Dibato: Writing\u2014Review and Editing. Selene R. T. Veerman: Writing\u2014Review and Editing. Rohit Aiyer Writing\u2014Review and Editing. Thomas N. Ferraro: Writing \u2013 Review and Editing. Gerardo Villarreal: Writing\u2014Review and Editing. Shafiqur Rahman: Writing\u2014Review and Editing. Trevor W. Stone: Writing \u2013 Review and Editing. Maju Mathew Koola: Conceptualization, Methodology, Investigation, Writing\u2014Review and Editing, Visualization, Supervision. Two biostatisticians (HH and WH) completed the formal statistical analysis. Houlin Hong and Jack Donlon prepared the manuscript. All authors edited the manuscript with intellectual contributions and approved the final version of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Veterans Affairs.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}